Related Experiment Video

Updated: Jul 21, 2026

Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device
10:51

Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device

Published on: August 30, 2016

22.4K

Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities

Jii Bum Lee1, Yiqing Huang2, Yuko Oya3

  • 1Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

Lung Cancer (Amsterdam, Netherlands)
|July 3, 2024
PubMed

Insights

The gut microbiome influences immunotherapy effectiveness in non-small cell lung cancer (NSCLC). Harnessing the microbiome, through fecal microbiota transplantation (FMT) or live biotherapeutic products (LBPs), may improve treatment outcomes for NSCLC patients.

Area of Science:

  • Oncology
  • Microbiome Research
  • Immunotherapy

Background:

  • Immunotherapy is effective for non-small cell lung cancer (NSCLC), but many patients relapse with few options.
  • Emerging research suggests the gut microbiome can enhance immunotherapy responses in epithelial tumors.
  • Understanding the lung and gut microbiome's role in NSCLC is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the role of the lung and gut microbiome in NSCLC.
  • To summarize mechanisms by which the microbiome affects chemotherapy and immunotherapy efficacy and toxicity.
  • To discuss ongoing clinical trials investigating microbiome-based therapies like fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) for NSCLC.

Main Methods:

  • Literature review of preclinical and clinical studies on the microbiome in NSCLC.
  • Analysis of proposed mechanisms linking microbiome composition to treatment response and toxicity.
  • Overview of current clinical trials involving microbiome modulation for NSCLC.

Main Results:

  • Preclinical data indicate microbiome modulation can improve immunotherapy efficacy.
  • The microbiome influences both the effectiveness and side effects of cancer treatments.
  • Clinical trials are actively exploring FMT and LBPs as novel NSCLC therapeutic strategies.

Conclusions:

  • The microbiome represents a promising target for enhancing NSCLC immunotherapy.
  • Further research into microbiome-gut-lung axis interactions is needed.
  • Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) show potential for improving NSCLC treatment.
Keywords:
ImmunotherapyMicrobiomeNon-small cell lung cancer

More Related Videos

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Related Concept Videos

What is Monogastric Digestion?01:50

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Dysbiosis of the Gut Microbiota01:18

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...